Quant Business Cycle Fund
The scheme seeks to generate long-term capital appreciation by investing with focus on riding business cycles through allocation between sectors and stocks at different stages of business cycles.
Growthvine rating: 4/5 — ranked #38 of 184 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹15.66 (as of 2026-10-01) |
|---|
| AUM | ₹985 Cr |
|---|
| Expense ratio | 1.93% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ayusha Kumbhat |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| Sharpe ratio | 0.38 |
|---|
| Standard deviation | 20.53% |
|---|
| Max drawdown | −30.87% |
|---|
| Alpha | 1.68 |
|---|
| Beta | 1.22 |
|---|
Over 5 years, captured 74.4% of NIFTY Alpha 50's upside and 75.6% of its downside.
Market cap allocation
| Large cap | 38.1% |
|---|
| Mid cap | 48.1% |
|---|
| Small cap | 13.7% |
|---|
Concentration
| Top 5 holdings | 46.9% |
|---|
| Top 10 holdings | 74.9% |
|---|
| Total holdings | 18 |
|---|
Top holdings
- TREPS 01-Sep-2026 DEPO 10 — 23.8%
- Piramal Finance Limited — 10.9%
- Aurobindo Pharma Ltd. — 10.1%
- Reliance Industries Limited 29/09/2026 — 9.3%
- INDUS TOWERS LIMITED — 8.6%
- Adani Green Energy Limited — 8.1%
- Infosys Limited 29/09/2026 — 6.9%
- Kotak Mahindra Bank Limited 29/09/2026 — 6.8%
- Samvardhana Motherson International Limited — 4.8%
- Premier Energies Limited — 4.8%
Top sectors
- Derivatives — 30.8%
- Pharma & Biotech — 12.0%
- Finance & Investments — 10.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 0.2% | Q2 | #58 of 167 |
| 2025 | −6.5% | Q4 (Bottom) | #125 of 132 |
| 2024 | 19.2% | Q3 | #50 of 86 |